The ABPI has today announced that Catherine Meaden has been appointed as the organisation’s new Director of Communications with immediate effect. She will lead the communications department and will be responsible for the ABPI’s engagement with government, NHS, media, patient groups and wider the healthcare community.
She will report directly to ABPI Chief Executive, Stephen Whitehead and will advise the Senior Leadership Team and Board of Management on communication issues. She will play a pivotal role in communicating to Government the value the pharmaceutical industry brings to the UK, through the creation of life changing medicines and as key driver of economic growth.
Catherine joined the ABPI in April 2012 as Head of Policy and Public Affairs.
Before working at the ABPI she headed up Marketing and Communications at NHS Direct – the telephone and online health advice service. During her time at NHS Direct she led their communications response to the swine flu pandemic. She has also worked in public affairs and campaigning roles at Cancer Research UK and the NHS Confederation.
Audrey Yvernault has been appointed to replace Catherine as Head of Policy and Public Affairs. She takes over this role having previously been Head of CEO and President External Affairs at the ABPI. Prior to this she was Head of Public Affairs at outsourcing company VT Group, and External Affairs Adviser at AstraZeneca.
Commenting, Stephen Whitehead, Chief Executive of the ABPI said:
“I am delighted by the appointment of Catherine as our new Director of Communications – her performance as our Head of Policy and Public Affairs was first rate and this appointment is thoroughly deserved. I look forward to working with Catherine as we continue to build a world class communications and advocacy function at the ABPI that speaks with a unified voice for the research based pharmaceutical industry.”
Commenting, Catherine Meaden, Director of Communications at the ABPI said:
“To be appointed to this role, as the UK pharmaceutical industry faces so many challenges, is hugely exciting. I will be communicating to our partners and stakeholders the continuing problems our companies face in getting their medicines to patients whilst highlighting the huge contribution industry makes to the UK.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.